GlaxoSmithKline (NYSE:GSK) has submitted its type 2 diabetes drug candidate to European regulators for approval.

Albiglutide, which will go by the name Eperzan, is an investigational injectible treatment for adults with type 2 diabetes. The drug is expected to compete against other injectible diabetes drugs, including Novo Nordisk’s daily injectible drug Victoza. GSK expects its once-weekly albiglutide will offer a dosing advantage.

Albiglutide was discovered and developed by Human Genome Sciences, which partnered with GSK on the compound. GSK last year acquired Human Genome Sciences in a $3.6 billion takeover. The compound is not not yet approved anywhere in the world but the drug maker has already taken steps to secure U.S. approval. GSK made its albiglutide regulatory filing to the Food and Drug Administration in January.

London-based GSK operates its U.S. headquarters in Research Triangle Park.